Novo Nordisk (NVO) Stock Rallies as FDA Forces Hims to Scrap Weight-Loss Pill

TLDR Novo Nordisk stock surged 8% Monday after Hims & Hers withdrew its $49 weight-loss pill under FDA pressure FDA announced plans to restrict compounded GLP-1 drugs, boosting Novo’s competitive position Hims & Hers stock dropped 14.8% in premarket trading following the product cancellation Novo’s market value has fallen nearly two-thirds since June 2024 due [...]

The post Novo Nordisk (NVO) Stock Rallies as FDA Forces Hims to Scrap Weight-Loss Pill appeared first on Blockonomi.